azulenyl-nitrone and Disease-Models--Animal

azulenyl-nitrone has been researched along with Disease-Models--Animal* in 3 studies

Reviews

1 review(s) available for azulenyl-nitrone and Disease-Models--Animal

ArticleYear
Diagnostic and therapeutic applications of azulenyl nitrone spin traps.
    Cellular and molecular life sciences : CMLS, 1999, Nov-15, Volume: 56, Issue:7-8

    Azulenyl nitrones have been recently demonstrated to constitute a new class of nitrone-based spin traps with the unprecedented capacity to tag free radicals by yielding characteristically colored and highly visible diamagnetic (and paramagnetic) spin adducts. In addition, a comparison of the oxidation potentials of azulenyl nitrones such as 1 and congeners to those of conventional nitrone spin traps previously investigated as potential antioxidant therapeutics such as N-tert-butyl-alpha-phenylnitrone and its related ortho-sodium sulfonate reveals that the azulene-derived spin traps are far more readily oxidized. These special features render azulenyl nitrones of interest with regard to both their distinct ability to engender the convenient use of colorimetric detection to monitor free radical-mediated oxidative stress in biological systems, and to their potentially enhanced efficacy as neuroprotective antioxidants vs. those conventional nitrone spin traps earlier examined as such. Herein is reported an overview of recent developments pertaining to the use of azulenyl nitrones in the detection of oxidative stress in animal models of amyotrophic lateral sclerosis and stroke, and to their neuroprotective activity in animal models of Parkinson's disease, stroke and neurodegeneration within the retina.

    Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Azulenes; Brain Ischemia; Disease Models, Animal; Dopamine; Humans; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Parkinson Disease; Retinal Ganglion Cells; Sesquiterpenes; Spin Trapping; Stroke; Superoxide Dismutase

1999

Other Studies

2 other study(ies) available for azulenyl-nitrone and Disease-Models--Animal

ArticleYear
Stilbazulenyl nitrone, a novel azulenyl nitrone antioxidant: improved neurological deficit and reduced contusion size after traumatic brain injury in rats.
    Journal of neurosurgery, 2002, Volume: 96, Issue:6

    Stilbazulenyl nitrone (STAZN) is a second-generation azulenyl nitrone that has markedly enhanced antioxidant properties compared with those of conventional alpha-phenyl nitrones. In this study, the authors assessed the potential efficacy of STAZN in a rodent model of fluid-percussion brain injury, which results in a consistent cortical contusion.. After anesthesia had been induced in normothermic Sprague-Dawley rats (brain temperature 36-36.5 degrees C) by halothane-nitrous oxide, the animals were subjected to a right parietooccipital parasagittal fluid-percussion injury (1.5-2 atm). The agent (STAZN, 30 mg/kg: eight animals) or vehicle (dimethyl sulfoxide; eight animals) was administered intraperitoneally at 5 minutes and 4 hours after trauma. The neurological status of each rat was evaluated on Days 1, 2, and 7 postinjury (normal score 0, maximum injury 12). Seven days after trauma, the rat brains were perfusion fixed, coronal sections at various levels were digitized, and areas of contusion were measured. Treatment with STAZN significantly improved neurological scores on Days 2 and 7 postinjury compared with vehicle-treated rats. Administration of STAZN also significantly reduced the total contusion area by 63% (1.8 +/- 0.5 mm2 in STAZN-treated animals compared with 4.8 +/- 2.1 mm2 in vehicle-treated animals; p = 0.04) and the deep cortical contusion area by 60% (1.2 +/- 0.2 mm2 in STAZN-treated animals compared with 2.9 +/- 1.2 mm2 in vehicle-treated animals; p = 0.03). By contrast, hippocampal cell loss in the CA3 sector was unaffected by STAZN treatment.. Therapy with STAZN, a novel potent antioxidant, administered following traumatic brain injury, markedly improves neurological and histological outcomes. Azulenyl nitrones appear to represent a promising class of neuroprotective agents for combating this devastating condition.

    Topics: Animals; Antioxidants; Azulenes; Brain Injuries; Disease Models, Animal; Male; Nervous System Diseases; Neuroprotective Agents; Nitrogen Oxides; Rats; Rats, Sprague-Dawley; Sesquiterpenes; Treatment Outcome

2002
Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis.
    Annals of neurology, 1998, Volume: 44, Issue:5

    Mutations of the SOD1 gene encoding copper/zinc superoxide dismutase (CuZnSOD) cause an inherited form of amyotrophic lateral sclerosis. When expressed in transgenic mice, the same SOD1 mutations cause progressive loss of spinal motor neurons with consequent paralysis and death. In vitro biochemical studies indicate that SOD1 mutations enhance free radical generation by the mutant enzyme. We investigated those findings in vivo by using a novel, brain-permeable spin trap, azulenyl nitrone. Reaction of azulenyl nitrone with a free radical forms a nitroxide adduct that then fragments to yield the corresponding azulenyl aldehyde. Transgenic mice expressing mutant SOD1-G93A show enhanced free radical content in spinal cord but not brain. This correlates with tissue-specific differences in the level of transgene expression. In spinal cord, the increase in free radical content is in direct proportion to the age-dependent increase in mutant human CuZnSOD expression. This increase precedes motor neuron degeneration. The higher level of human CuZnSOD expression seen in spinal cord compared with brain, and consequent difference in free radical generation, provides a basis for understanding the selective vulnerability of the spinal cord in this disease model.

    Topics: Aging; Amyotrophic Lateral Sclerosis; Animals; Azulenes; Brain; Disease Models, Animal; Free Radicals; Gene Expression Regulation, Developmental; Gene Expression Regulation, Enzymologic; Humans; Mice; Mice, Transgenic; Nitrogen Oxides; Point Mutation; Sesquiterpenes; Spin Labels; Spinal Cord; Superoxide Dismutase; Superoxides

1998